NVO - Novo Nordisk - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

409.1B

Cash

36.41B

Avg Qtr Burn

N/A

Short % of Float

0.19%

Insider Ownership

0.01%

Institutional Own.

8.22%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Etavopivat (FT-4202) (PKR activator) Details Sickle cell disease	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT-7051 (CBP/P300 inhibitor) Details Castration-resistant prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.